Modular update: Equality and health inequality impact assessment (EHIA)
Closed for comments This consultation ended on at Request commenting lead permission
5 References
Action for Pulmonary Fibrosis (2026) Benefit claims for pulmonary fibrosis [online; accessed 29 January 2026]
Anthony Nolan (2021) Returning to work after a stem cell transplant: Information for patients [online; accessed 29 January 2026]
Atogepant for preventing migraine: Equality impact assessment (2024) NICE technology appraisal guidance 973
Baricitinib for treating severe alopecia areata: Equality impact assessment (2023) NICE technology appraisal guidance 926
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over: Equality impact assessment. (2024) NICE technology appraisal guidance 949
Biz AN, Hernández Alava M, Wailoo A (2026) Switching from EQ-5D-3L to EQ-5D-5L in England: the impact in NICE technology appraisals. Value in Health (forthcoming)
Cancer Research UK (2022) First data in a decade highlights ethnic disparities in cancer [online; accessed 17 December 2025]
Cladribine for treating active relapsing forms of multiple sclerosis: Equality impact assessment. (2025) NICE technology appraisal guidance 1053
Clostridium botulinum neurotoxin type A for treating chronic sialorrhoea: Equality impact assessment. (2019) NICE technology appraisal guidance 605
Daridorexant for treating long-term insomnia: Equality impact assessment (2023) NICE technology appraisal guidance 922
Deucravacitinib for treating moderate to severe plaque psoriasis: Equality impact assessment (2023) NICE technology appraisal guidance 907
Dupilumab for treating moderate to severe prurigo nodularis: Equality impact assessment (2024) NICE technology appraisal guidance 955
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over: Equality impact assessment (2025) NICE technology appraisal guidance 1051
Filgotinib for treating moderately to severely active ulcerative colitis: Equality impact assessment (2022) NICE technology appraisal guidance 792
Foslevodopa-foscarbidopa for treating Parkinson's with motor symptom: Equality impact assessment (2023) NICE technology appraisal guidance 934
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over: Equality impact assessment (2025) NICE technology appraisal guidance 1101
HM Government (2010) Equality Act 2010 [online; accessed 25 February 2026]
Linzagolix for treating symptoms of endometriosis: Equality impact assessment (2025) NICE technology appraisal guidance 1067
Lupus Trust UK (2022) Is lupus a disability? [online; accessed 29 January 2026]
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over: Equality impact assessment. (2025) NICE technology appraisal guidance 934
Nusinersen for treating spinal muscular atrophy: Equality impact assessment (2019) NICE technology appraisal 588
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over: Equality impact assessment. (2025) NICE technology appraisal guidance 1088
Secukinumab for treating moderate to severe hidradenitis suppurativa: Equality impact assessment (2023) NICE technology appraisal guidance 935
Tixagevimab plus cilgavimab for preventing COVID-19: Equality impact assessment (2023) NICE technology appraisal guidance 900
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over: Equality impact assessment (2025) NICE technology appraisal guidance 1031
Wailoo A, Biz AN, Hernández Alava M (2026) What is the impact of EQ-5D-5L vs 3L on NICE severity weights? NICE DSU report
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions